EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Therapeutic Immune Reprogramming by Rapamycin Attenuates Plaque Inflammation and Lymphoid Immune Responses in Aged Atherosclerotic Mice

Jill de Mol iD, Daphne H de Korte iD, Marie A C Depuydt iD, Virginia Smit iD, Mireia N A Bernabé Kleijn iD, Peter J van Santbrink, Christoph J Binder iD, Florentina Porsch iD, Frank H Schaftenaar, Amanda C Foks iD

Aging Cell · 2026

DOI: 10.1111/acel.70730 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Aging Cell, 2026. Verfasst von Jill de Mol und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of BioTherapeutics, Leiden Academic Centre for Drug Research, Leiden University, Leiden, the Netherlands. Hauptthemen laut MEDLINE: Sirolimus, Inflammation, Plaque, Atherosclerotic, Atherosclerosis. Die Arbeit nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hartstichting, European Union, ERA-4Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aging is a major risk factor for atherosclerosis and is accompanied by profound changes in the immune system, including effector T cell expansion, senescent cell accumulation, and increased pro‐inflammatory signaling. Rapamycin, a promising rejuvenation therapeutic that inhibits mTORC1 and modulates immune aging, was investigated for its potential to attenuate pro‐atherogenic immune responses in aged atherosclerotic mice. 80‐ to 90‐week‐old male Ldlr −/− mice with established atherosclerotic lesions were treated intraperitoneally with rapamycin or control triweekly for 8 weeks. Systemic and plaque immunity was assessed by flow cytometry or single‐cell RNA‐sequencing. Plaque morphology was evaluated by histology. Rapamycin treatment reduced plaque macrophage content (0.73 ± 0.07 × 10 5 μm 2 ) compared to control (ctrl: 0.95 ± 0.09 × 10 5 μm 2 , p < 0.05) and decreased total T cell numbers in vascular and lymphoid tissues. This was accompanied by a shift from effector to central memory phenotypes, particularly within the CD8 + compartment, and a relative enrichment of regulatory CD4 + T cells (Tregs). Single‐cell transcriptomics of aortic Tregs revealed increased expression of suppressive genes ( Foxp3 , Tgfb1 ) upon rapamycin. Rapamycin also reduced T follicular helper cells, IL‐21 expression, germinal center B cells, plasma cells, and total and oxidation‐specific epitope‐specific immunoglobulin levels. Additionally, age‐associated B cells were diminished in spleen and lymph nodes, reflecting a broader anti‐inflammatory effect on B cell immunity. Finally, aortic leukocytes displayed profoundly reduced senescent enrichment scores. Rapamycin remodels the immune landscape in aged atherosclerotic mice, promoting regulatory lymphocyte subsets and suppressing antigen‐driven and inflammatory immune responses. These findings highlight the potential of immune‐targeted rejuvenation to mitigate age‐related atherogenic inflammation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SirolimusInflammationPlaque, AtheroscleroticAtherosclerosisAgingAnimalsMiceMale

Stichwörter der Autor:innen

agingatherosclerosisbasic science researchimmunologysenescencevascular disease

Substanzen

Sirolimus

Autor:innen und Institutionen

  • Division of BioTherapeutics, Leiden Academic Centre for Drug Research, Leiden University, Leiden, the Netherlands.
  • Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria.

ORCID-Profile: Jill de Mol, Daphne H de Korte, Marie A C Depuydt, Virginia Smit, Mireia N A Bernabé Kleijn, Christoph J Binder, Florentina Porsch, Amanda C Foks

Förderung

  • Hartstichting
  • European Union
  • ERA-4Health
  • the AtheroNETH consortium, Dutch Heart Foundation
  • the Treat-ATHERO consortium, Dutch Heart Foundation
  • European Commission

Zitieren

APA

de Mol, J., de Korte, D. H., Depuydt, M. A. C., Smit, V., Kleijn, M. N. A. B., van Santbrink, P. J., Binder, C. J., Porsch, F., Schaftenaar, F. H., & Foks, A. C. (2026). Therapeutic Immune Reprogramming by Rapamycin Attenuates Plaque Inflammation and Lymphoid Immune Responses in Aged Atherosclerotic Mice. Aging Cell. https://doi.org/10.1111/acel.70730

Vancouver

de Mol J, de Korte DH, Depuydt MAC, Smit V, Kleijn MNAB, van Santbrink PJ, et al. Therapeutic Immune Reprogramming by Rapamycin Attenuates Plaque Inflammation and Lymphoid Immune Responses in Aged Atherosclerotic Mice. Aging Cell. 2026. doi:10.1111/acel.70730

BibTeX
@article{deMol2026,
  author = {de Mol, Jill and de Korte, Daphne H and Depuydt, Marie A C and Smit, Virginia and Kleijn, Mireia N A Bernabé and van Santbrink, Peter J and Binder, Christoph J and Porsch, Florentina and Schaftenaar, Frank H and Foks, Amanda C},
  title = {Therapeutic Immune Reprogramming by Rapamycin Attenuates Plaque Inflammation and Lymphoid Immune Responses in Aged Atherosclerotic Mice},
  journal = {Aging Cell},
  year = {2026},
  doi = {10.1111/acel.70730}
}
Kostenlos starten →